Raymond Schuch

17PUBLICATIONS
6CO-AUTHORS
Powder and particle technologyBiocatalysis and enzyme technologyMicrobial ecologyMedical bacteriologyMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Feb 17, 2024
The Engineered Lysin CF-370 Is Active Against Antibiotic-Resistant Gram-Negative Pathogens In Vitro and Synergizes With Meropenem in Experimental Pseudomonas aeruginosa Pneumonia.

Karen Sauve, Aubrey Watson, Jun T Oh

|Aug 10, 2023
Rapid bacteriolysis of Staphylococcus aureus by lysin exebacase.

Xavier Vila-Farres, Karen Sauve, Jun Oh

|Mar 02, 2023
The Lysin Exebacase Has a Low Propensity for Resistance Development in Staphylococcus aureus and Suppresses the Emergence of Resistance to Antistaphylococcal Antibiotics.

Jun Oh, Matthew Warner, Jane E Ambler

|Jul 21, 2022
Activity of Exebacase (CF-301) against Biofilms Formed by Staphylococcus epidermidis Strains Isolated from Prosthetic Joint Infections.

Aubin Souche, Camille Kolenda, Jordan Teoli

|Aug 16, 2021
Exebacase in Addition to Daptomycin against MRSA.

Razieh Kebriaei, Kyle C Stamper, Katherine L Lev

|Jul 05, 2021
Efficacy assessment of lysin CF-296 in addition to daptomycin or vancomycin against Staphylococcus aureus in the murine thigh infection model.

Tomefa E Asempa, Nicole A DeRosa, Cara Cassino

Pageof 3

Frequent Collaborators

2 joint publications

Robin Patel

1 joint publications

Daniel C Nelson

1 joint publications

Patricia A Bradford

1 joint publications

Tomefa E Asempa